![\"Top](\"https:\/\/static.toiimg.com\/thumb\/msid-132393403,imgsize-625453,width-400,height-225,resizemode-4\/top-stocks-to-buy.jpg\" "\\"Top")
<\/div>\n<\/div>\n<\/div>\nStock market recommendations<\/span>:<\/span> Route Mobile<\/span>, <\/span>Tata Power<\/span>, and <\/span>Dr. Reddy’s Laboratories<\/span> – these are the top stocks to buy picked by Mehul Kothari, DVP – Technical Research at Anand Rathi Shares for July 15, 2026.<\/span> Route Mobile: Bullish Breakout Signals Fresh Upside Potential<\/span>Buy: Rs 584\u2013Rs 575 | Stop Loss: Rs 525 | Target: Rs 680<\/span>Route Mobile has witnessed a decisive breakout from its consolidation range, indicating the beginning of a fresh bullish phase. The stock is trading comfortably above both the 20-DEMA and 50-DEMA, reflecting improving short- to medium-term trend strength. Additionally, the price has moved above the Ichimoku Cloud, signalling a shift in the overall trend from neutral to bullish.Momentum indicators further support the positive outlook, with the MACD trading above the zero line, confirming strengthening buying momentum. This combination of a range breakout, positive trend alignment, and improving momentum suggests that the stock could continue its upward trajectory. Traders may consider accumulating the stock in the Rs 584\u2013Rs 575 zone for a target of Rs 680.Tata Power: Reversal Setup Emerging from Key Fibonacci Support<\/span>Buy: Rs 380\u2013Rs 370 | Stop Loss: Rs 357 | Target: Rs 410<\/span>Tata Power is showing encouraging signs of a potential reversal after completing an ABCD corrective pattern, with Point D aligning near the 1.27 external Fibonacci extension and a strong historical demand zone around Rs 365\u2013Rs 375. This area also coincides with the Monthly Floor Pivot S1, strengthening the support base.The recent correction has retraced nearly 78.6% of the previous upmove, while the Cumulative Volume Delta (CVD) has formed a bullish divergence, indicating that selling pressure is gradually easing despite lower price lows. In addition, the RSI has rebounded from oversold territory and is attempting to move above the 40 mark, signalling improving momentum. This confluence of support, volume behaviour, and momentum suggests a favourable risk-reward setup for a medium-term recovery. Traders may consider accumulating the stock in the Rs 380\u2013Rs 370 range for a target of Rs 410.Dr. Reddy’s Laboratories: Fresh Breakout Signals Continuation of the Uptrend<\/span>Buy: Rs 7,125\u2013Rs 7,075 | Stop Loss: Rs 6,600 | Target: Rs 8,100<\/span>Dr. Reddy’s Laboratories has witnessed a decisive breakout above the Rs 7,000\u2013Rs 7,050 resistance zone after a prolonged consolidation, confirming a continuation of the broader uptrend. The breakout has been accompanied by improving price structure, with the previous resistance now expected to act as a strong support zone, offering a favourable risk-reward opportunity on declines.Momentum indicators are also supporting the positive outlook, with the RSI moving above the 60 mark and registering a positive crossover, indicating strengthening buying momentum. The combination of a strong breakout, improving momentum, and a favourable long-term trend suggests that the stock is well-positioned for further upside. Traders may consider accumulating the stock in the Rs 7,125\u2013Rs 7,075 range with a stop loss at Rs 6,600 for an upside target of Rs 8,100 over the medium term.(Disclaimer: Recommendations and views on the stock market, or any other asset classes or personal finance management tips given by experts and analysts are their own. These opinions do not represent the views of The Times of India.)<\/span><\/div>\n